Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by Benedictuson Dec 29, 2023 11:46pm
178 Views
Post# 35804912

RE:RE:Early warrant exercise

RE:RE:Early warrant exercise
matt2018 wrote: I dont see how any news can be released during this period of the discounted exercise of warrants period of Jan 16 to Feb 15.
Looks like they would like to raise $6.5M during this period through this discount from $1.50 to $1.00.
I guess they are hoping on the stock price being higher than a buck during this period or why would investors exercise them?

Right, just guessing here, but it seems likely they would want to announce the start of p2 prior to this "incentive" window opening up and then bank on that confirmation driving the sp higher and bringing the wts itm.  But unless we also get confirmation of an arbitration win I just don't know how comfortably itm they can get those wts. Also, the optics of an even further price reduction and thus managements current perception of the company's valuation is really poor imo. 
<< Previous
Bullboard Posts
Next >>